Sanofi and GSK are in advanced discussions with the European Commission (EC) for the supply of up to 300 million doses of a COVID-19 vaccine.
The vaccine candidate developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK’s established adjuvant technology. The doses would be manufactured in European countries including France, Belgium, Germany and Italy. This marks a key milestone in protecting and serving the European population against COVID-19.
“Today’s announcement helps to ensure that millions of Europeans will have access to a potential vaccine protecting against COVID-19, once proven safe and effective. It has been our steadfast commitment to provide a vaccine that is affordable and accessible to everyone, and we are grateful to the European Commission for their ongoing engagement and shared support of this effort,” said Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur. “Together with GSK, we are working relentlessly to develop and produce a vaccine to address this global health crisis.”
Roger Connor, President of GSK Vaccines added: “GSK is proud to be working with Sanofi to make this vaccine available as soon as possible in Europe. Both companies have significant R&D and manufacturing capability in Europe and we are working hard to scale up production across our networks. This announcement from the EC supports our ongoing efforts.”
Sanofi expects a Phase 1/ 2 study to start in September, followed by a Phase 3 study by the end of 2020. If data are positive, regulatory approval could be achieved by the first half of 2021. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant to produce up to one billion doses per year overall.